Navigating the complex landscape of benzodiazepine- and Z-drug diversity: insights from comprehensive FDA adverse event reporting system analysis and beyond

Filip Koniuszewski, Florian Vogel, Irena Dajić, Thomas Seidel, M Kunze, Matthäus Willeit, Margot ErnstFrontiers in Psychiatry 2023 · DOI

TL;DR

Benzodiazepines and Z-drugs, commonly prescribed for anxiety and sleep, are not as interchangeable as often assumed. This study reveals significant differences in their adverse event profiles, suggesting a need for more personalized prescribing and further investigation into the molecular basis of these diverse effects.

What Problem Does This Paper Address?

Benzodiazepines (BZDs) and Z-drugs (like zolpidem) are widely used psychoactive medications that target GABA-A receptors. Despite their common mechanism of action and broad therapeutic uses (anxiolytic, hypnotic, anticonvulsant), there's a lack of detailed, comparative understanding of their individual adverse effect profiles. This gap makes it difficult to optimize treatment, manage side effects, and develop safer alternatives. The authors aim to address this by systematically analyzing real-world adverse event data to uncover drug-specific patterns and explore their potential molecular underpinnings.

Methods

The core of this study involved a large-scale pharmacovigilance analysis using the US Food and Drug Administration's Adverse Event Reporting System (FAERS) database.

  • Disproportionality Analysis: The researchers employed disproportionality analysis, specifically calculating the Information Component (IC025), to identify statistically significant associations between individual drugs and reported adverse events (AEs). This method helps to flag potential safety signals that might be missed by simpler frequency counts.
  • Sex-Specific Analysis: Crucially, the analysis was performed separately for male and female patient reports to uncover potential sex-based differences in drug effects.
  • MedDRA Hierarchy: Adverse events were categorized using the Medical Dictionary for Regulatory Activities (MedDRA) hierarchy, allowing for analysis at different levels of specificity (System Organ Class, High Level Group, etc.).
  • Physico-chemical Descriptors & 3D Structure Analysis: To explore the molecular basis of observed differences, the authors used ligand fingerprint analysis and pharmacophore modeling to group compounds based on their chemical properties and 3D structures.

Datasets

  • FAERS Database: The primary dataset used was the US FDA Adverse Event Reporting System (FAERS), specifically reports collected from Q1 2004 to Q3 2021. This dataset contains millions of drug-adverse event combinations.
  • Drugbank, Wikipedia, Wikidata: These sources were used to compile an initial list of 173 benzodiazepines and Z-drugs.

Key Insights and Ideas

  • Drug Heterogeneity is Significant: The most striking insight is that BZDs and Z-drugs, often treated as a class, exhibit remarkably diverse adverse event profiles. This heterogeneity is too broad to be explained solely by the canonical "diazepam-sensitive high-affinity binding sites" on GABA-A receptors.
  • Sex Differences Matter: The analysis revealed significant sex-specific differences in adverse event reporting for many drugs, suggesting that sex is a crucial factor in drug response and safety.
  • Beyond Canonical Binding Sites: The diverse AEs point towards the involvement of additional binding sites on GABA-A receptors or synergistic interactions with endogenous substances (like steroids and endocannabinoids) in mediating drug effects.
  • Specific Drug Signatures: Certain drugs showed unique patterns of adverse events. For example, eszopiclone was strongly associated with insomnia, while its racemic precursor, zopiclone, had a more varied profile including associations with self-injurious behavior.
  • Abuse Potential and Amnesia: The study highlighted specific drugs (e.g., lormetazepam, clorazepate) with a strong association with amnestic effects, particularly in females, raising concerns about their potential for non-medical use, including as "date rape" drugs.

Key Results

  • The analysis identified a "multifaceted FAERS picture," indicating substantial differences in adverse event profiles across individual BZDs and Z-drugs.
  • Specific adverse events, such as paradoxical responses (e.g., logorrhoea), showed stronger associations in males for certain drugs.
  • Anterograde amnesia was found to be strongly associated with lormetazepam and clorazepate, particularly in female reports, with a notable absence of this association for males.
  • While etizolam and brotizolam showed similar FAERS profiles, eszopiclone and zopiclone, despite being enantiomers/racemates, displayed distinct and largely non-overlapping top adverse event profiles.

Limitations and Future Work

  • FAERS Limitations: The authors acknowledge the inherent limitations of FAERS data, including potential reporting biases, missing dosage information, lack of demographic data, and the inability to establish causation.
  • Need for Clinical Validation: They emphasize that these findings are signals and require substantiation through more thorough clinical and pharmacoepidemiological investigations.
  • Molecular Basis: While physico-chemical descriptors and 3D structure analysis provided some insights, the precise molecular drivers of observed heterogeneity require further exploration.
  • Sex-Specific Factors: The study suggests that sex differences may not solely be due to reporting bias but could involve complex biological interactions, warranting further research.
  • Future Directions: The authors propose that these insights can inform drug development, clinical decision-making, and potentially lead to updated product information and legal classifications for individual compounds.

Summary updated

Abstract

We found a multifaceted FAERS picture, and suggest that more thorough clinical and pharmacoepidemiologic investigations of the heterogenous side effect profiles for benzodiazepines and Z-drugs are needed. This may lead to more differentiated safety profiles and prescription practice for particular compounds, which in turn could potentially ease side effect burden in everyday clinical practice considerably. From both preclinical literature and pharmacovigilance data, there is converging evidence that this very large class of psychoactive molecules displays a broad range of distinctive unwanted effect profiles - too broad to be explained by the four canonical, so-called "diazepam-sensitive high-affinity interaction sites". The substance-specific signatures of compound effects may partly be mediated by phenomena such as occupancy of additional binding sites, and/or synergistic interactions with endogenous substances like steroids and endocannabinoids. These in turn drive the wanted and unwanted effects and sex differences of individual compounds.
BibTeX
@inproceedings{koniuszewski2023navigating,
  author = {Filip Koniuszewski and Florian Vogel and Irena Dajić and Thomas Seidel and M Kunze and Matthäus Willeit and Margot Ernst},
  title = {{Navigating the complex landscape of benzodiazepine- and Z-drug diversity: insights from comprehensive FDA adverse event reporting system analysis and beyond}},
  booktitle = {Frontiers in Psychiatry},
  year = {2023},
  doi = {10.3389/fpsyt.2023.1188101},
}
Figure